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Summary
The Epstein–Barr virus (EBV) is one of the most common human viruses, infecting more than 
90% of the world’s adult population. In some individuals the interplay between EBV replication, 
latency and immune control can be disrupted and evokes prolonged proliferation of EBV-infected 
lymphocytes and their malignant transformation. Since its discovery as the first human tumor 
virus, EBV has been implicated in the development of a wide range of human cancers. The evi-
dence for an association with EBV is the strongest for Burkitt’s lymphoma, NK/T cell lymphoma, 
nasopharyngeal carcinoma, Hodgkin’s lymphoma and for malignant lymphomas in immune in-
competent patients. Additionally, certain epithelial cell tumors, such as gastric carcinoma and 
breast carcinoma, have been defined as EBV related. However, the virus may be encountered in 
other types of malignancies. The oncogenic potential of EBV is related to its ability to infect and 
transform B lymphocytes into continuously growing lymphoblastoid cell lines. EBV encodes a 
series of products mimicking several growth, transcription and anti-apoptotic factors, to usurp 
control of the pathways that regulate diverse homeostatic cellular functions. However, the exact 
mechanism by which EBV promotes oncogenesis remains unclear. The focus of this review is to 
summarize the current knowledge of oncogenic potential of the Epstein–Barr virus and its role 
in the pathogenesis of EBV-associated lymphoproliferative disorders.
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IntroductIon
Epstein-Barr virus (EBV), also called human herpes virus 
4 (HHV-4), was the first human virus to be directly impli-
cated in carcinogenesis. EBV is a part of the Herpesviridae 
family [99,117]. It was discovered by Michael Epstein and 
Yvonne Barr in 1964 during their research on Burkitt’s 
lymphoma (BL) [32]. Since its discovery, EBV has been 
found in a variety of other tumor types. The evidence for 
an association with EBV is the strongest for BL, NK/T-cell 
lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s 
lymphoma (HL) and for malignant lymphomas in immune 
incompetent patients [47]. Additionally, certain epithelial 
cell tumors, such as gastric carcinoma [107] and breast 
carcinoma [5], have been found to be EBV related [78]. 
However, the virus may be encountered in other types 
of malignancies.
Like other members of the Herpesviridae, EBV virions 
have a double-stranded, linear DNA genome encoding 
approximately 100 genes surrounded by a protein cap-
sid. A protein tegument lies between the capsid and the 
envelope. Mature virions are 120-180 nm in diameter. 
EBV infects more than 90% of the world’s adult popula-
tion. Infection usually occurs early in childhood. EBV 
infections are most prevalent in developing countries, 
in populations of low socioeconomic status [42, 116]. In 
countries with stringent hygiene practices, EBV serop-
revalence tends to increase gradually with age, showing 
two seroconversion peaks: at 2 to 4 years and at 14 to 18 
years [41]. The mean seroprevalence in children is ap-
proximately 50% and increases steadily to a value of 90% 
to 99% in adults [4].
There are two major strains of EBV (type 1 and type 2), 
differing in organization of the genes that encode the 
EBV nuclear antigen (EBNA) [90]. Both types are detected 
all over the world, with type 1 being the most frequent, 
although in some regions (e.g. central Africa, Papua New 
Guinea and Alaska) type 2 definitely predominates [37, 
94]. The virus is passed to uninfected individuals with sa-
liva or spread through close oral contact, but transmission 
by transfusion has also been documented [7]. 
In spite of frequent virus detection in latently infected 
blood donors, transmission of EBV infection by trans-
fusion is thought to be relatively infrequent. This phe-
nomenon could be explained by the fact that most adult 
recipients of blood and blood products are already im-
mune to EBV. Moreover, blood from seropositive donors 
contains EBV-neutralizing antibodies and specific mem-
ory cells, which may protect the recipient from infec-
tion. Although we do not know exact EBV infectivity by 
blood and its components, it seems that the viral load in 
blood from healthy seropositive donors, which is nor-
mally low (5/106-1/107 peripheral blood mononuclear 
cells), is rather below an infection dose. In addition, it 
was established that the viability of B lymphocytes car-
rying the EBV genome may decline during blood storage. 
The risk of EBV transmission from red blood cell (RBC) 
and/or platelet (PLT) transfusions is also significantly 
reduced by leukoreduction. Thus, in most instances, EBV 
genomes contained in blood products should not cause 
severe disease when the transfused recipient is immune 
competent. However, whole blood and blood components 
as a potential source of infection should be kept in mind 
as an association between transfusion and EBV infection, 
especially in immunosuppressed young patients, is still 
being discussed [104].
Most primary EBV infections in normal individuals are 
unapparent, but occasionally EBV can cause acute infec-
tious mononucleosis, which is a self-limited disease. Fol-
lowing primary EBV infection, individuals remain lifelong 
carriers of the virus. EBV then persists latently in the host 
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within long-life memory B cells [73]. The growth of B cells 
latently infected with EBV is normally controlled by the 
host immune response, particularly by virus-specific T 
cells [41]. However, in some individuals, the virus is im-
plicated in the development of malignancy [25]. It is well 
documented that in the immunocompromised hosts, the 
interplay between EBV replication, latency and immune 
control can be disrupted and evokes prolonged prolifera-
tion of EBV-infected lymphocytes and their malignant 
transformation [17, 34]. There are hypotheses that there 
is an association between EBV infection and autoimmune 
[31, 111] and allergic diseases [61,97].
EBV can infect both B cells [9] and epithelial cells [100]. 
The role of epithelial cells in the life cycle of EBV is still 
incompletely defined. It is generally believed that epithe-
lial cells in the oropharynx represent the site of primary 
EBV infection and replication [10]. This is followed by a 
latent infection of B lymphocytes. The B-lymphotropic 
nature of EBV is evidenced by the ability to immortalize 
normal resting B lymphocytes in vitro, converting them 
into permanently growing lymphoblastoid cell lines (LCL) 
[93]. EBV-infected B lymphocytes carry the viral genome 
in a latent form. In some circumstances, EBV latency may 
reactivate, resulting in the expression of viral genes en-
coding series of products stimulating anti-apoptotic mol-
ecules, cytokines, and signal transducers [77]. Disrupted 
control of the cellular pathways regulating a wide vari-
ety of homeostatic cellular functions leads to neoplastic 
transformation.
In healthy individuals, EBV is latently maintained in 
memory B cells, which express only the transcripts for 
EBV small RNAs (EBERs). This state is termed latency 0 
and allows for persistence of the virus in a way that is 
nonpathogenic and not detectable by the immune sys-
tem [103].
Three types of latent genes have been described (Fig-
ure 1). Type I latency, characterized by the expres-
sion of Epstein–Barr nuclear antigen 1 (EBNA-1) and 
two small noncoding Epstein–Barr RNAs (EBERs), was 
found in BL [19]. EBV gene expression in latency II, 
associated with classic HL and T-cell non-Hodgkin’s 
lymphoma [91], is limited to EBNA-1, EBERs, latent 
membrane protein (LMP)-1, LMP-2A and LMP-2B. La-
tency III usually involves the unrestricted expression 
of all EBNAs, EBERs, and LMPs [22] and occurs mainly 
in immunocompromised individuals suffering from 
post-transplant lymphoproliferative disorders (PTLDs), 
HIV-associated lymphoproliferative disorders and in 
lymphoblastoid cell lines [117].
Fig. 1. Three forms of Epstein-Barr virus latency 
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The ability of EBV to efficiently transform B cells in 
culture to immortalized, transformed cells undoubt-
edly accentuates its connection to human cancers [83]. 
Although EBV may be essential for tumorigenesis, it is 
not generally sufficient on its own. Other factors such 
as specific failure of immune recognition, stimulation 
of B-cell proliferation by other infections, appearance 
of secondary genetic aberrations or mutations may also 
be important [99].
EBV usually infects B cells via the B-cell specific CD21 
antigen [35] and EBV-associated hematologic malignan-
cies are predominantly of B cell type. In addition, EBV is 
associated with rare T- and NK-cell malignancies [53,59]. 
EBV-positive lymphomas can be divided into those oc-
curring in immunodeficient individuals, which are true 
virally driven lymphomas, such as PTLD and HIV-associ-
ated immunoblastic lymphoma, and those occurring in 
immunocompetent individuals.
EBV-assocIatEd lymphomas 
In ImmunocompEtEnt IndIVIduals 
Burkitt’s lymphoma
BL is an aggressive lymphoma associated with EBV infec-
tion. It is classified as a non-Hodgkin’s lymphoma (NHL) 
and has the fastest doubling time among human tumors 
[27]. Based on clinical and epidemiological characteristics 
BL is subdivided into three categories: endemic BL (eBL), 
sporadic BL (sBL), and HIV-associated BL. Studies suggest 
that variations differ in geographical distribution and de-
gree of association with EBV. About 95% of eBL cases are 
associated with EBV and are commonly found in equato-
rial Africa and Papua New Guinea [105, 118]. In contrast, 
only 5–15% of sBL, affecting children and young adults, 
throughout the world and 40% of HIV-associated BL are 
EBV positive [115]. Subtypes of BL also differ in clinical 
manifestation. Typically, eBL presents as tumors affecting 
the jaw and facial bones, while sBL more commonly arises 
in the gut and upper respiratory tract, forming tumors in 
the Waldeyer ring [13, 119]. HIV-associated BL characteris-
tically involves the lymph nodes and bone marrow [12]. For 
all three types of BL, males are more commonly affected 
than females [101]. 
The mechanism by which EBV contributes to the develop-
ment of Burkitt’s lymphoma is not entirely understood. 
The EBV associated BL demonstrates that the complex 
interaction of EBV with B cells predisposes to BL devel-
opment [74, 101]. Malaria infection in endemic regions 
is considered as another co-factor for the development 
of BL [16]. It is assumed that hyperstimulation of B cells 
and suppression of T-cell activity by malaria allow for re-
activation of EBV in infected B cells, which consequently 
increase in numbers. The alternative explanation is that 
malaria infection compromises EBV-specific immune 
control, leading to immune escape of an EBV-infected B 
cell including those in which a c-myc translocation has 
occurred [11]. 
In all variations of BL, constitutive activation of the 
c-myc oncogene through its translocation into one of 
the immunoglobulin loci is clearly the key factor of the 
oncogenesis [118]. 80% of all BL shows a t(8:14) trans-
location; the other observed translocations are t(8:22) 
and t(8:2) [3, 30]. The translocation is dependent on 
the enzyme activity of AID (activation-induced cyti-
dine deaminase) [44, 80]. AID is highly expressed in the 
germinal center (GC) to provide the class switch and 
hypermutation of the Ig variable region. After trans-
location, the activated myc can lead to cell growth and 
proliferation; however, it also leads to apoptosis in the 
absence of apoptosis-inhibiting signals. These signals 
may be provided by EBV proteins (EBNA-1) [8, 76]. Some 
studies have shown BL cases that do not show any MYC 
translocation, yet still overexpress c-myc. This has been 
demonstrated for <10% of sBL and linked to miRNA de-
regulation [1].
Most EBV-positive cases exhibit a restrictive pattern of 
expression of latent encoded proteins, only expressing 
EBNA-1 and the EBERs (latency I) [118]. Because EBNA-1 
protein is poorly antigenic and has little to no HLA class 
I response, the CD8+ T-cell response to BL is largely di-
minished. Various pathways by which BL escapes immune 
detection by inhibiting both HLA class I- and II-mediated 
Ag presentation to T cells are essential to the disease 
pathogenesis [36,72].
It was recently reported that some cases, in addition 
to EBNA-1 and the EBERs, express EBNA-3A, EBNA-3B, 
EBNA-3C, and EBNA leader protein but still lack EBNA-
2 and the latent membrane proteins [60]. EBNA-1 plays 
a crucial role in the maintenance and replication of 
the viral genome, but its oncogenic potential is highly 
controversial [114,118]. Conversely, as the EBERs are 
believed to possess anti-apoptotic activity, it has been 
postulated that they may play an essential role in the 
oncogenesis of BL [62].
Hodgkin’s lymphoma
Hodgkin’s lymphoma accounts for about 1% of all can-
cers and 30% of lymphoid malignancies worldwide [43]. 
Epidemiologic studies of HL demonstrate a remarkable 
diversity of the incidence according to age, sex, eth-
nicity, geographic location and socioeconomic status 
[21,51]. According to the WHO classification, HL can be 
histologically divided into four subtypes: lymphocyte 
predominant (LP), nodular sclerosing (NS), mixed cel-
lularity (MC) and lymphocyte depleted (LD) [38]. Not all 
subtypes harbor EBV to the same degree. EBV positivity 
in lymphoma tissue is discerned in 70% of MC Hodg-
kin’s disease, 95% of LD Hodgkin’s disease, and 10–40% 
of NS. LP Hodgkin’s disease subtype is almost always 
EBV negative [24].
The role that EBV plays in HL is still not fully under-
stood. Several lines of evidence including increased 
risk in individuals with a past history of infectious   
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mononucleosis [2], elevated antibody titers to EBV vi-
ral capsid antigen [71] and demonstration of the vi-
rus in the malignant cells [110] link EBV to HL. HL is 
characterized by an expansion of Hodgkin and Reed-
Sternberg (HRS) cells representing transformed B cells 
and constituting a minority of the tumor mass [67]. 
The feature of HRS cells is constant activation of anti-
apoptotic transcription factor NF-κB, essential for HRS 
cell survival [85].
EBV-positive HL has expression of EBNA-1, LMP-1, 
LMP-2 and the EBERs, indicative of type 2 latency [28]. 
HRS cells often have destructive immunoglobulin vari-
able (V) gene mutation and therefore lose expression 
of the B-cell receptor (BCR). Germinal-centre B cells 
that acquire such mutations are normally eliminated 
by apoptosis in the germinal centre. The current sce-
nario for HL is that the expression of latent membrane 
protein 1 (LMP-1) and LMP-2A may prevent apoptosis 
by mimicking CD40 and BCR signaling, respectively. 
[57, 65]. Furthermore, to evoke its own survival, HRS 
cells employ several mechanisms, which are able to 
suppress a supportive microenvironment of immune 
and stromal cells and local immune responsiveness 
[33]. HRS cells have been shown to produce immuno-
suppressive cytokines such as IL-10, IL-13 and TGF-β 
[39,45,58,72] as one of the elements of immune escape 
in Hodgkin’s lymphoma.
T-cell lymphomas
In contrast to its role in B-lymphomagenesis, EBV has 
only incidentally been associated with T-cell lymphomas. 
Several types of non-B-cell non-Hodgkin’s lymphoma are 
associated with EBV [48, 52]. We will focus on angioim-
munoblastic and nasal T/NK cell lymphoma. 
Angioimmunoblastic T-cell lymphoma (AITL) is a rare 
neoplasm but represents the most common subtype of pe-
ripheral T-cell lymphomas [50]. Viral genome is detected 
in up to 100% of AITL lymph nodes [109]. However, EBV 
can be detected only in B cells [14]. The presence of EBV 
in only a subpopulation of cells suggests that EBV infec-
tion is secondary to malignancy or that the viral genome 
has been lost from the malignant cell [99]. AITL is char-
acterized by systemic disease, a polymorphous infiltrate 
primarily involving lymph nodes, proliferation of high 
endothelial venules and follicular dendritic cells [113]. 
Clinically it occurs as a widespread lymphadenopathy, 
extranodal disease, immune-mediated hemolysis, and 
polyclonal hypergammaglobulinemia, and presents poor 
prognosis [46].
Nasal-type T/NK-cell lymphoma is a rare tumor, al-
most always associated with EBV, prevalent in Asia and 
especially in China [49]. Nasal T/NK lymphoma cells ex-
hibit several unique genotypic and phenotypic features. 
Fig. 2. Pathogenesis of CAEBV
 
       -               -               -               -               -       486
Postepy Hig Med Dosw (online), 2013; tom 67: 481-490
These features include an absence of T-cell antigens, the 
expression of the NK cell marker CD56, and the absence 
of T-cell receptor gene rearrangement [112]. The nasal 
region is the most frequent site of involvement but the 
tumor may also appear at other extranodal sites such 
as skin, testis, kidney, upper gastrointestinal tract, and 
the orbit [23, 88]. 
Some nasal NK/T-cell lymphomas develop from long-
lasting EBV infection termed chronic active EBV infec-
tion (CAEBV). CAEBV is an EBV-associated syndrome 
characterized by a variety of serious hematological dis-
orders, including malignant lymphoma. EBV was found 
to infect circulating T and/or NK cells in patients with 
CAEBV. These EBV-infected cells express EBNA-1, LMP-1, 
and LMP-2A, a type II form of EBV latency, which is also 
observed in nasopharyngeal carcinoma (NPC), HL, and 
peripheral T-cell lymphoma. CAEBV may thus represent 
a subset of EBV-associated T- and/or NK-cell lymphopro-
liferative disorders [56]. Most lymphomas associated with 
CAEBV have been reported to be nodal T-cell [55, 82] but 
in some cases extranodal T-cell lymphoma was diagnosed 
in the skin, kidneys, spleen, pancreas, and meninges [6]. 
Figure 2 presents the pathogenesis of CAEBV.
EBV-assocIatEd lymphomas In ImmunocompromIsEd IndIVIduals 
Patients with primary immunodeficiencies such as Wis-
kott-Aldrich syndrome, severe combined immunodefi-
ciency (SCID) or X-linked lymphoproliferative disease 
are prone to develop EBV-related lymphoproliferative 
disorders (LPDs). However, EBV-related LPDs are more 
frequent in patients with secondary immunodeficiencies 
with AIDS or in organ transplant recipients who receive 
immunosuppressive therapy [26].
HIV-associated lymphoproliferative disorders
HIV-associated lymphoproliferative disorders represent 
a heterogeneous group of diseases, arising in the pres-
ence of HIV-associated immunodeficiency. According to 
the WHO classification, HIV-associated lymphomas are 
categorized into: (a) lymphomas also occurring in immu-
nocompetent patients, including BL, diffuse large B-cell 
lymphoma (DLBCL) with centroblastic/immunoblastic 
features, extranodal marginal zone lymphoma of MALT 
type, peripheral T-cell lymphoma and HL; (b) lymphomas 
occurring more specifically in HIV-positive patients, in-
cluding primary effusion lymphoma and plasmablastic 
lymphoma of the oral cavity; (c) lymphomas also occur-
ring in other immunodeficiency states, including poly-
morphic B-cell lymphoma (PTLD-like) [84]. The increased 
risk for lymphoma among HIV-infected individuals ap-
pears to be related to multiple factors, including duration 
and degree of immunosuppression, induction of cyto-
kines leading to B-cell proliferation, and opportunistic 
infections with oncogenic herpesviruses such as EBV 
and HHV-8 [64]. The evidence of EBV involvement in de-
velopment of HIV-related lymphomas is the demonstra-
tion of monoclonal virus in the tumors. EBV is present 
in approximately 60% of HIV-related lymphomas, but the 
proportion of virus-positive tumors varies depending on 
histological subtype [26].
BLs make up the largest group of HIV-associated non-
Hodgkin lymphomas, comprising 35–50% of these neo-
plasms [95]. The presence of latent EBV in BL cells has 
been shown to promote genetic instability [54], suggest-
ing a mechanism by which latent EBV could contribute 
to genetic alterations required for the development of BL. 
Other studies have shown that the priming of circulating 
EBV-specific CD8+ T cells is dependent on CD4+ T cells 
[81]. In HIV-infected individuals the CD4+ T-cell count 
is greatly reduced, leading to diminished CD8+ T-cell ac-
tivity which permits reactivation of EBV-infected B cells 
[81]. High frequency of EBV association has been shown 
in HL (80%–100%) tissues from HIV-infected people. Ad-
ditionally, EBV-encoded LMP-1 is expressed in all HIV-HL 
cases [86, 89], which shows that HL in HIV-infected per-
sons appears to be an EBV-driven lymphoma [20].
Immunoblastic DLBCL has a high frequency of EBV posi-
tivity (80–90%) with frequent expression of LMP-1 and 
EBNA-2. LMP-1 plays a crucial role in the transforma-
tion of B-lymphocytes by EBV into immortalized human 
primary B cells [29] by activating NF-κβ and other anti-
apoptotic factors [66,108].
DLBCL also gives rise to the primary central nervous sys-
tem lymphoma (PCNSL) in AIDS patients [68]. PCNSL is 
extremely rare in the general population but occurs in 
0.5% of patients with AIDS and shows EBV association in 
100% of cases [70]. 
Most cases of primary effusion lymphomas (PELs) are 
dually infected with EBV and Kaposi’s sarcoma associ-
ated herpesvirus (KSHV) [75]. While PEL is a rare tumor 
in immunocompetent individuals, it arises with increased 
incidence rates in HIV-infected patients. The exact role 
of EBV is unclear but the fact that both viruses are de-
tected together in most cases suggests that EBV may act 
as a cofactor in the initiating events (because it can im-
mortalize and transform B cells in vitro) whereas HHV-8 
may be the driving force for the tumor [92]. 
Post-transplant lymphoproliferative disease
EBV has also been linked to most post-transplant lympho-
proliferative disease (PTLD) cases, with a near 100% asso-
ciation. Type III latency is exhibited by the EBV-positive B 
cells in PTLD [15]. The wide expression of the latent EBV-
encoded proteins suggests an important role that EBV 
play in the oncogenic process. The mechanism by which 
EBV is thought to contribute to the pathogenesis of PTLD 
is similar to its presumed role in HL. As approximately 
50% of PTLD cases are derived from GC B cells lacking a 
functional BCR because of certain crippling mutations, 
and because these cells manage to escape apoptosis de-
spite lacking antigen affinity, it is believed that EBV aids 
in rescuing these cells from apoptosis [18, 102].  
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PTLD is a spectrum of lymphoid hyperproliferative states 
that may be observed in solid organ and bone marrow 
transplant recipients [69]. The majority of cases of post-
transplant lymphoma (PTL) are EBV-positive [98]. Iatro-
genic immunosuppression leading to primary EBV infec-
tion or reactivation of latent EBV infection is followed by 
polyclonal expansion of B cells. These cells are suscep-
tible to molecular aberrations driving malignant growth 
[63]. Inadequate T-cell control of EBV-infected B lym-
phocytes is thought to be critical to the development of 
EBV-positive PTLDs. Decreased anti-EBV nuclear antigen 
antibody levels have been associated with an increased 
risk for PTLD [87]. Other predisposing factors include 
EBV mismatch between donor and recipient, high levels 
of immune suppression, transplanted organ type and cy-
tomegalovirus infection [69,96].
However, there is no consensus whether any particular 
immunosuppressive agent is particularly responsible 
for PTLD. It seems that the risk of PTLD is rather low 
in patients treated with prednisone and azathioprine 
while the data on muromonab-CD3 and various forms 
of anti-thymocyte globulins suggest they probably in-
crease the risk of PTLD. PTLD is commonest in children 
under 10 years and adults over 60 years, reaching the 
highest frequency in pediatric small bowel transplant 
recipients and the lowest in adult liver transplant re-
cipients (Table 1) [79].
Table 1. Frequency of PTLD in patients after different organ transplantations 
by age [116].
Organ Adults (%) Pediatric (%)
Kidney 1.0-2.3 1.2-10.1
Liver 1.0-2.8 4.0-15.0
Heart/lung 2.4-5.8 6.4-19.5
Lung 4.2-10.0 6.4-19.5
Heart 1.0-6.3 6.4-19.5
The cumulative incidence of PTLD in allogeneic hema-
topoietic stem cell transplantation (HSCT) recipients is 
1.0% (range 0.5-1.8%). Major risk factors for the early 
development of PTLD in allo-HSCT recipients include the 
use of unrelated or HLA-mismatched related donors, T-
cell depletion of donor marrow, and use of anti-thymo-
cyte globulin or monoclonal anti-T-cell antibodies for 
the prophylaxis and treatment of acute graft-versus-host 
disease [106].
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